Plethora Solutions

Plethora Solutions Holdings plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical treatments for premature ejaculation in the area of men's sexual health. The Company is engaged in the development of new pharmaceutical products, which it refers to as Plethora Development. The Company has developed PSD502, which is a treatment for premature ejaculation, and has also completed phase III clinical trials. The PSD502 is also authorized to be marketed under the name of Prilocaine Lidocaine Plethora through the European Medicines Agency (EMA). Its subsidiaries include Plethora Solutions Limited and Plethora Therapeutics Limited.

Chalgrove, GB
Size (employees)
5 (est)
Plethora Solutions is headquartered in Chalgrove, GB

Plethora Solutions Office Locations

Plethora Solutions has an office in Chalgrove
Chalgrove, GB (HQ)
Warpsgrove Ln

Plethora Solutions Data and Metrics

Plethora Solutions Financial Metrics

Plethora Solutions's revenue was reported to be £3.9 m in FY, 2014

Net income (FY, 2015)

(4.3 m)

Cash (31-Dec-2015)

91 k
GBPFY, 2013FY, 2014FY, 2015


3.9 m

Pre tax profit

(1.5 m)(9.2 m)(4.5 m)

Net Income

(1.5 m)(9.2 m)(4.3 m)
GBPFY, 2013FY, 2014FY, 2015


608 k3.5 m91 k

Current Assets

641 k3.8 m519 k


76 k60 k

Total Assets

641 k3.9 m579 k

Accounts Payable

104 k224 k484 k

Current Liabilities

29.6 m41.3 m41.2 m

Total Liabilities

29.6 m41.3 m41.2 m

Retained Earnings

(1.5 m)(9.2 m)(4.3 m)

Total Equity

(28.9 m)(37.5 m)(40.6 m)

Financial Leverage

0 x-0.1 x0 x
GBPFY, 2014FY, 2015

Cash From Operating Activities

3 m(3.2 m)

Income Taxes Paid

195 k

Plethora Solutions Company Life and Culture

You may also be interested in